This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Thermo Fisher Scientific is a scientific instrument maker and a world leader in serving science. In Nov 2006, Thermo Fisher Scientific, Inc. was formed through the merger of Thermo Electron Corporation with Fisher Scientific International Inc. On Feb 3, 2014, Thermo Fisher acquired Life Technologies Corporation. Following the acquisition, the new reporting segments are: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Align Technology Rides on Invisalign Amid Coronavirus Woes
by Zacks Equity Research
Align Technology's (ALGN) Invisalign clear aligner has been receiving positive feedback and holds huge long-term market potential.
BD Gets CE Mark for Point-of-Care Coronavirus Antigen Test
by Zacks Equity Research
BD (BDX) receives CE mark for its rapid, point-of-care, SARS-CoV-2 antigen test for use on the BD Veritor Plus System.
Here's Why You Should Retain Cardinal Health Stock for Now
by Zacks Equity Research
Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment, diversified product portfolio and strategic buyouts.
Teleflex's (TFX) Arrow EZ-IO Gets FDA's Expanded Indications
by Zacks Equity Research
Teleflex's (TFX) recent expanded indications for its IO device provide more time to physicians to establish safe vascular access.
Here's Why You Should Retain OPKO Health (OPK) Stock for Now
by Zacks Equity Research
Investor confidence is high on OPKO Health (OPK), thanks to solid prospects.
Why Thermo Fisher (TMO) Could Beat Earnings Estimates Again
by Zacks Equity Research
Thermo Fisher (TMO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Quest Diagnostics' 3-in-1 Coronavirus Test Launch Well Timed
by Zacks Equity Research
According to Quest Diagnostics (DGX), under such situation, laboratory testing that can reliably identify the virus causing disease will be critical to mobilize effective patient care.
Zacks.com featured highlights include: Thor Industries, Thermo Fisher Scientific, Big Lots, Sapiens International and Fortune Brands Home & Security
by Zacks Equity Research
Zacks.com featured highlights include: Thor Industries, Thermo Fisher Scientific, Big Lots, Sapiens International and Fortune Brands Home & Security
LabCorp Coronavirus Test Sales Aid Growth Amid Volume Woes
by Zacks Equity Research
There has been a steady recovery in the Base Business of LabCorp (LH).
5 Cheap Dividend Growth Stocks to Buy Amid Volatility
by Sweta Killa
Stock market volatility and near-zero interest rates have been driving the appeal for dividend investing.
Thermo Fisher (TMO) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Thermo Fisher (TMO) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Here's Why You Should Invest in LHC Group (LHCG) Stock Now
by Zacks Equity Research
LHC Group (LHCG) continues to gain traction from its broad range of services, and strategic acquisitions and joint ventures.
Thermo Fisher Rides on End Market Growth, Test Revenues
by Zacks Equity Research
Thermo Fisher's (TMO) pharma and biotech end markets register growth on robust performance in bioproduction and pharma services businesses.
Here's Why You Should Hold on to Hologic (HOLX) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Hologic (HOLX) on robust growth of the Diagnostics segment and regulatory approvals.
Nike, OrganiGram, Thermo Fisher, Danaher Corp and Agilent Tech highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Nike, OrganiGram, Thermo Fisher, Danaher Corp and Agilent Tech highlighted as Zacks Bull and Bear of the Day
Hologic (HOLX) Receives EUA for Asymptomatic Coronavirus Testing
by Zacks Equity Research
The FDA approves Hologic's (HOLX) Panther Fusion SARS-CoV-2 assay and pooling protocol to curb the unrelenting spread of coronavirus.
Medtronic, Axonics Patent War Continues for Sacral Neuromodulation (Revised)
by Zacks Equity Research
Medtronic's (MDT) InterStim system electrically stimulates the sacral nerves.
3 Picks to Ride the Coronavirus-Led Strength in Lab Plastic Space
by Urmimala Biswas
These laboratory equipment suppliers' fate does not depend on the end result of the R&D outcomes of the drug and vaccine makers.
Veeva Collaborates With RedHill for Coronavirus Clinical Study
by Zacks Equity Research
RedHill has adopted Veeva's (VEEV) Vault CDMS platform for the opaganib study.
Here's Why You Should Retain Change Healthcare (CHNG) Stock
by Zacks Equity Research
Change Healthcare (CHNG) continues to benefit from robust payment accuracy business and strategic deals. However, intense competition remains a woe.
Surmodics' Pounce Thrombus Retrieval System Gets FDA Nod
by Zacks Equity Research
The FDA clearance of Surmodics' (SRDX) Pounce Thrombus Retrieval System will bolster the current treatment of complex PAD.
The Zacks Analyst Blog Highlights: Procter & Gamble, Verizon, Thermo Fisher Scientific, Nvidia and Nike
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Procter & Gamble, Verizon, Thermo Fisher Scientific, Nvidia and Nike
Thermo Fisher Scientific (TMO) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Thermo Fisher Scientific (TMO) closed the most recent trading day at $428.39, moving +1.44% from the previous trading session.
Syneos Health Banks on Essential Therapies Amid Coronavirus Woe
by Zacks Equity Research
Syneos Health's (SYNH) over 70% of clinical businesses comprise essential therapeutic areas that are experiencing reduced impacts of coronavirus outbreak.
Medtronic Wins Neuromodulation Patent Dispute Against Axonics
by Zacks Equity Research
Medtronic's (MDT) InterStim system electrically stimulates the sacral nerves.